The stem cell assay market is estimated to be valued at US$ 1.6 Billion in 2022 and is expected to exhibit a CAGR of 16.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Stem cell assays are techniques used to study properties of stem cells such as differentiation, proliferation, apoptosis and more. These assays are widely used in research activities associated with development of new drugs and therapeutic applications of stem cells. Common applications include disease modeling, toxicity testing and drug discovery.
Market Dynamics:
The demand for stem cell assays is expected to increase significantly over the forecast period owing to rising technological advancements and increasing investments in R&D activities associated with stem cells. Growing prevalence of chronic diseases such as cancer is also driving the focus on development of new drugs using stem cells. Stem cell therapy is considered a promising area in treatment of various diseases. Growth in stem cell banking and availability of commercial assay kits are further anticipated to fuel the market growth during the forecast period. However, high costs associated with stem cell research and reluctance of some countries to legalize stem cell therapy are key factors expected to restrain the market to some extent.
SWOT Analysis
Strength: Stem cell assays have high sensitivity and specificity for drug discovery and development. They aid in cell-based screening at an early stage to identify toxic compounds. Further, stem cell assays help understand disease pathology and cell biology mechanisms.
Weakness: Stem cell assays require specialized infrastructure and trained personnel for stem cell handling and differentiation. High costs associated with stem cell culture and assays limit their widespread adoption.
Opportunity: Increasing R&D in regenerative medicine provides scope to apply stem cell assays for developing novel cell therapies. Growing stem cell banking industry also drives demand.
Threats: Strict regulatory norms for stem cell research may delay assay approvals. Ethical issues linked to embryonic stem cells restrain their utility in some regions.
Key Takeaways
The global Stem Cell Assay Market Share is expected to witness high growth, exhibiting a CAGR of 16.5% over the forecast period, due to increasing investments in stem cell-based research. Stem cell therapies hold potential to treat various diseases.
Regional analysis: North America dominates the market due to presence of advanced research infrastructure and funding. However, Asia Pacific is likely to grow at the fastest pace during the analysis period on back of increasing healthcare spending by governments in India and China.
Key players: Key players operating in the stem cell assay market are Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad Laboratories, Promega Corporation, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio-Techne Corporation, STEMCELL Technologies, and Cellular Dynamics International
Read More,
https://www.trendingwebwire.com/stem-cell-assay-market-trends-size-and-share-analysis/
